<DOC>
	<DOCNO>NCT00066768</DOCNO>
	<brief_summary>This randomized phase I trial study side effect best dose suramin give together either docetaxel gemcitabine treat patient stage IIIB stage IV non-small cell lung cancer refractory platinum chemotherapy ( cisplatin , carboplatin , oxaliplatin ) . Drugs use chemotherapy docetaxel gemcitabine use different way stop tumor cell divide stop grow die . Some tumor become resistant chemotherapy drug . Combining suramin either docetaxel gemcitabine may reduce resistance drug kill tumor cell .</brief_summary>
	<brief_title>Suramin Either Docetaxel Gemcitabine Treating Patients With Stage IIIB Stage IV Platinum-Refractory Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety low-dose suramin administer docetaxel gemcitabine patient stage IIIB IV platinum-refractory non-small cell lung cancer . II . Determine , preliminarily , antitumor activity regimens patient . III . Determine whether suramin plasma concentration combination docetaxel gemcitabine predict pretreatment dose calculation base clinical parameter . OUTLINE : This randomize , pilot , dose-finding study . Patients randomize 1 2 treatment arm . ARM I : Patients receive low-dose suramin IV 30 minute docetaxel IV 1 hour day 1 . ARM II : Patients receive low-dose suramin IV 30 minute gemcitabine IV 30 minute day 1 8 . In arm , treatment repeat every 3 week 3 course absence unacceptable toxicity . Patients complete partial response initial 3 course optionally continue therapy 3 additional course . Patients disease progression 6 course treatment original arm may cross receive treatment arm . Patients progressive disease stable disease initial 3 course cross arm receive treatment arm 3 additional course . Patients responsive stable disease sixth course may continue therapy arm . Cohorts 6-12 patient arm receive dos suramin calculate clinical formula validate prior clinical trial . Adjustments suramin dose perform initial dose target le 50 ÂµM peak concentration . The optimal dose define dose least 5 6 patient achieve optimal plasma concentration suramin 1 6 patient experience dose-limiting toxicity . In event dose-limiting toxicity , dose docetaxel gemcitabine adjust optimal dose combination suramin determine . Patients follow least 30 day .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Suramin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically cytologically confirm nonsmall cell lung cancer Stage IIIB* IV Progressive disease prior platinumcontaining regimen ( e.g. , cisplatin , carboplatin , oxaliplatin ) No know brain leptomeningeal disease , unless follow true : Lesions previously irradiate No concurrent corticosteroid No clinical symptom Performance status ECOG 02 At least 12 week Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.0 g/dL Bilirubin great 1.5 mg/dL AST/ALT great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN Creatinine great 2.0 mg/dL No myocardial infarction within past 6 month No congestive heart failure require therapy No unstable angina Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active serious infectious process No grade 2 great neuropathy No uncontrolled diabetes mellitus No psychiatric disorder would preclude give informed consent interfere study followup See Disease Characteristics At least 28 day since prior cytotoxic chemotherapy recover No 2 prior chemotherapy regimens No prior docetaxel No prior gemcitabine See Disease Characteristics See Disease Characteristics Prior radiotherapy allow At least 2 week since prior epidermal growth factor receptor therapy Prior suramin allow No concurrent antiHIV medication HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>